Dendreon, Pharmacyclics and Other Biotech Takeover Targets Nelson Hem, Benzinga Staff Writer July 10, 2012 2:07 PM + FollowPrintEmail
M&A in the biotech and pharmaceutical industries continues. Bristol-Myers Squibb (NYSE: BMY) just announced it has agreed to acquire Amylin Pharmaceuticals (NASDAQ: AMLN) for $5.3 billion. And Human Genome Sciences (NASDAQ: HGSI) has opened itself up to bidders, including GlaxoSmithKline (NYSE: GSK). Other rumored takeover targets in the sector include Arena Pharmaceuticals (NASDAQ: ARNA), Cubist Pharmaceuticals (NASDAQ: CBST), Dendreon (NASDAQ: DNDN), Pharmacyclics (NASDAQ: PCYC) and Vertex Pharmaceuticals (NASDAQ: VRTX).